Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPI | P09923 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | XIAP | P98170 | 1/20 | 0.58 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.58 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.54 |
| ▸ | MMP2 | P08253 | 2/20 | 0.54 |
| ▸ | CTSC | P53634 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | MME | P08473 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8788898 | 1.00 | ALPI (0.58) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL8789703 | 1.00 | ALPI (0.58) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL26605058 | 0.94 | ALPI (0.51) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL26605063 | 0.94 | ALPI (0.51) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Trifluoroacetic Acid SCHEMBL404848 | 0.93 | ALPI (0.50) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Benzene SCHEMBL11575909 | 0.89 | SLC7A5 (0.58) | SLC7A5MMP2 | |
| Benzene SCHEMBL11575906 | 0.89 | SLC7A5 (0.58) | SLC7A5MMP2 | |
| SCHEMBL1329815 | 0.88 | MME (0.62) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL6047673 | 0.88 | MME (0.62) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL1329817 | 0.88 | MME (0.62) | ALPIPKMPTGS1XIAPSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3130608-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | Daiichi Sankyo Co., Ltd. (JP) | 2017-02-15 | — | — | EP | disclosed |
| US-8981049-B2 | Aziridine mediated native chemical ligation | WASHINGTON STATE UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| US-20130131311-A1 | AZIRIDINE MEDIATED NATIVE CHEMICAL LIGATION | WASHINGTON STATE UNIVERSITY (US) | 2013-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131311-A1 | AZIRIDINE MEDIATED NATIVE CHEMICAL LIGATION | PTMS, NGLY1, DNPEP | ALPI 1716/4885PKM 4344/4885PTGS1 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.